An Article by Prof. Reisner and His Team Reporting Success of Pig Embryonic Pancreatic Transplantation in Diabetic Mice Has Been Elected for Publication in PLoS Medicine.

HERZLIYA, Israel -- Tissera, Inc. (OTCBB:TSSR) reports that an article entitled "Embryonic Pig Pancreatic Tissue Transplantation for the Treatment of Diabetes," authored by Prof. Yair Reisner and his team at the Weizmann Institute of Science, has been elected for publication in the much renowned and appreciated scientific journal, PLoS Medicine, (PLoS stands for Public Library of Science), and has appeared in its June 20, 2006 online edition (http://www.plos.org/).

The research referred by the article has been performed and sponsored by Tissera at the Weizmann Institute of Science, drawn on the premises that ways might be found to utilize various porcine fetal tissues for transplantation into human patients in need. The Company's R&D efforts are directed towards the accomplishment of its mission to develop and commercialize such a transplantation technology, thus providing a universally available and reliable source of donor organs to those so many patients awaiting organ transplantation, who currently suffer from the severe shortage of donor organs. The research results featuring in the article underscore the achievement of an important milestone in the implementation of the Company's technology development program in the domain of the treatment of type I diabetes mellitus, namely the demonstration of the curative potential of the Company's approach in diabetic mouse models.

Since the achievement of this milestone, the Company has moved forward to experiments in primates, and, subsequent to previously reported favorable results of transplantation in non-diabetic primates, is currently actively engaged in studies of pig embryonic pancreatic tissue transplantation in primate diabetic models. Those current studies aim at further demonstrating, in higher animals, the functional and therapeutic value of the Company's approach.

The publication of the article in PLoS Medicine has been commented by a press release by the Weizmann Institute of Science, which can be read at: http://80.70.129.162/site/en/weizman.asp?pi=371&doc_id=4536.

About Tissera

Tissera is a biotechnology company dedicated to the development of novel tissue precursor regeneration technologies for treating gene deficiencies and diseases in which organ transplantation is necessary, while minimizing the dosage of immunosuppressive drugs. Tissera obtained the license for the worldwide exclusive rights to the technology developed by Professor Yair Reisner and his team at the Weizmann Institute of Science in Israel. In this research, scientists successfully implanted in mice embryonic human and porcine organ precursor tissues, which grew into functional organs. This research was published in Nature Medicine and attracted worldwide scientific and media attention.

About PLoS Medicine

PLoS Medicine is an international, multidisciplinary medical journal that aims to publish outstanding human studies that substantially enhance the understanding of human health and disease. It aims to promote translation of basic research into clinical investigation, and of clinical evidence into practice. It encourages papers that cross disciplines.

Safe Harbor Statement

"Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding our developing technology into a useful product, our moving forward with our plans for trials, and our plans to expand the Company's infrastructure. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Such statements, including statements regarding freedom to operate, patentability, infringement, clinical trials, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), competitive risks to marketed products and availability of financing that could cause actual results to differ materially include risks and uncertainties such as the inability to further finance our plans and unforeseen technical difficulties in developing our technology, which could among other things, delay or prevent product development and our planned results. For further risk factors see the Company's 10-KSB filed with the SEC for our latest fiscal year."